VKTX
Viking Therapeutics Inc
NASDAQ: VKTX · HEALTHCARE · BIOTECHNOLOGY
$25.36
+1.89% today
Updated 2026-10-28
Market cap
$3.20B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.67
Dividend yield
—
52W range
$25 – $43
Volume
5.5M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.5
Quality
B+3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
2.8
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$94.50
+272.63%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
5 Strong Buy13 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-125.17M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-68.87M | $-85.89M | $-109.96M | $-359.64M | $-128.02M |
| EPS | — | — | — | — | $-4.67 |
| Free cash flow | $-48.40M | $-73.38M | $-87.79M | $-278.69M | $-125.17M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Viking Therapeutics Inc trades at $25.36. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 2.76, it sits in the grey zone.
Frequently asked questions
What is Viking Therapeutics Inc's stock price?
Viking Therapeutics Inc (VKTX) trades at $25.36.
Is Viking Therapeutics Inc overvalued?
Viking Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Viking Therapeutics Inc (VKTX)?
The 12-month analyst consensus target is $94.50, about 272.6% above the current $25.36. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Viking Therapeutics Inc's Altman Z-Score is 2.76, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-70.00%
Beta0.65
50D MA$32.17
200D MA$32.76
Shares out0.13B
Float0.11B
Short ratio—
Avg volume5.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—